MAFA
NBIX icon

MJT & Associates Financial Advisory’s Neurocrine Biosciences NBIX Stock Holding History

MJT & Associates Financial Advisory’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.68K Buy
+33
New +$5.3K ﹤0.01% 275
2026
Q2 		– Sell
-30
Closed -$3.95K – 482
2026
Q1 		$3.95K Hold
30
– – ﹤0.01% 301
2025
Q4 		$4.25K Hold
30
– – ﹤0.01% 304
2025
Q3 		$4.21K Buy
+30
New +$4.07K ﹤0.01% 318

Other funds holding NBIX

CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
ACM
Argent Capital Management St Louis, Missouri $3.14B AUM 31.36% 1-Year Est. Return
RSC
Red Spruce Capital Berwyn, Pennsylvania $283M AUM 29.49% 1-Year Est. Return
MNBTD
Moody National Bank Trust Division Galveston, Texas $1.21B AUM 28.25% 1-Year Est. Return
JWS
Juncture Wealth Strategies Scottsdale, Arizona $390M AUM 19.15% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
WWM
Whalen Wealth Management Las Vegas, Nevada $234M AUM 28.06% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
PCS
Private Client Services Louisville, Kentucky $372M AUM 17.65% 1-Year Est. Return
CCAL
City Center Advisors LLC Troy, Michigan $131M AUM 24.02% 1-Year Est. Return

MJT & Associates Financial Advisory's NBIX Position: Q3 2026 in Review

MJT & Associates Financial Advisory opened a new position in Neurocrine Biosciences (NBIX) in Q3 2026: 33 shares worth $4.68K. The stake represents ﹤0.01% of the portfolio and ranks #275 among its holdings. This is a return to the name: MJT & Associates Financial Advisory previously reported a position in NBIX as recently as Q1 2026.

MJT & Associates Financial Advisory first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 21 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • MJT & Associates Financial Advisory held 33 shares of Neurocrine Biosciences worth $4.68K as of Q3 2026.
  • Neurocrine Biosciences was a new MJT & Associates Financial Advisory position in Q3 2026.
  • Neurocrine Biosciences made up ﹤0.01% of MJT & Associates Financial Advisory's portfolio in Q3 2026, its #275 holding.
  • MJT & Associates Financial Advisory first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 21 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on MJT & Associates Financial Advisory's 13F filing for Q3 2026, filed 7 Oct 2026.